|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
BioVascular Inc.
| | | Phone: | (858) 455-5000 | Fax: | (858) 455-6200 | Year Established: | 2005 | Main Contact: | Paul F. Glidden, Ph.D., VP, Development | | Other Contacts: | Alison J. Pilgrim, MD, Ph.D., CMO & VP, Clinical Research & Regulatory Affairs John H. Parrish, President & CEO
| | Company Description | BioVascular is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006. | |
|
|
|
|
|